大日住薬：Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) - 有報キャッチャー

大日住薬（4506）　Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) 2020/12/24

/-

読み込み中…